We placed @entity1 with @entity43 into four distinct prognostic groups: 'low', 'moderate', 'high' and 'extreme' risk. The 'moderate-risk' group contained all residual negative, stage I and II @entity1 with two exceptions: stage Ia or b, grade 1 @entity5 and grade 3 @entity5 . They were treated with primary surgery, usually including bilateral salpingo-oophorectomy, hysterectomy and omentectomy. Chemotherapy was then given ( @entity900 at 100 mg m-2 every 2 weeks for three cycles) followed by pelvi-abdominal irradiation (2250 cGy in 10 fractions to the pelvis and 2250 cGy in 22 fractions to the whole abdomen including pelvis). An early cohort with ascites or positive washings instead received six cycles of @entity900 and @entity786 at 75 mg m-2 and 600 mg m-2 every 4 weeks with the same pelvi-abdominal irradiation sandwiched between cycles 3 and 4. One-hundred and nine @entity1 were treated between November 1983 and December 1989. Median follow-up was 4.7 years (range 0.7-9 years). The 5-year actuarial overall and failure-free survivals were 81% and 76%, respectively. @entity137 , although usually minor, included 15% with @entity1897 or @entity2167 and 23% with chronic abdominal complaints. Our combined-modality results are similar to those obtained by other centers utilizing either pelvi-abdominal irradiation alone or @entity900 -based chemotherapy alone.

'Moderate-risk' @entity43 (stage I, grade 2; stage II, grade 1 or 2) treated with XXXX chemotherapy (single agent or combination) and pelvi-abdominal irradiation.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity43 :: ('MESH:D010051', 'Disease') :: ['invasive epithelial ovarian cancer'] @entity137 :: ('MESH:D064420', 'Disease') :: ['Chronic toxicity'] @entity2167 :: ('MESH:D006311', 'Disease') :: ['ototoxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity1897 :: ('MESH:D010523', 'Disease') :: ['peripheral neuropathy']
@entity900 :: (MESH:D002945,Chemical) :: ['cisplatin']
